Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Non-Current Deffered Revenue: 2020-2022

Historic Non-Current Deffered Revenue for Molecular Partners Ag (MOLN) over the last 3 years, with Dec 2022 value amounting to $3.8 million.

  • Molecular Partners Ag's Non-Current Deffered Revenue fell 71.81% to $1.6 million in Q2 2023 from the same period last year, while for Jun 2023 it was $1.6 million, marking a year-over-year decrease of 71.81%. This contributed to the annual value of $3.8 million for FY2022, which is 49.73% down from last year.
  • Latest data reveals that Molecular Partners Ag reported Non-Current Deffered Revenue of $3.8 million as of FY2022, which was down 49.73% from $7.5 million recorded in FY2021.
  • Molecular Partners Ag's Non-Current Deffered Revenue's 5-year high stood at $7.5 million during FY2021, with a 5-year trough of $3.3 million in FY2020.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $3.8 million (2022), whereas its average is $4.8 million.
  • Per our database at Business Quant, Molecular Partners Ag's Non-Current Deffered Revenue spiked by 131.01% in 2021 and then crashed by 49.73% in 2022.
  • Over the past 3 years, Molecular Partners Ag's Non-Current Deffered Revenue (Yearly) stood at $3.3 million in 2020, then surged by 131.01% to $7.5 million in 2021, then crashed by 49.73% to $3.8 million in 2022.